By elucidating the mechanisms underlying NK cell dysfunction in DLBCL, our findings will not only deepen the understanding of the immune landscape in these patients, but also lay the groundwork for the development of novel immunotherapies targeting TIGIT and its associated pathways. The gene discussed is TIGIT; the disease is diffuse large B-cell lymphoma.